PAREXEL Cuts Clinical Trial Start-up Time for Sponsors by Weeks with New Version of Industry-leading ClinPhone RTSM Services
Latest RTSM technology features standardized study components for faster implementation and greater design flexibility
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of a new version of its industry standard ClinPhone® RTSM services designed to help clients start clinical trials more quickly. The leading edge randomization and trial supply management (RTSM) solution has been used in more than 3,000 studies involving over 400,000 sites and two million patients since 1996. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials® platform, an integrated suite of applications for managing clinical trials.
Biopharmaceutical companies are increasingly seeking to make drug development more efficient without compromising patient safety or data quality. Efficiency is particularly critical at the start of clinical trials, when clients must simultaneously initiate a broad range of important activities such as patient screening, enrollment and randomization, as well as drug dispensation and supply distribution.
Addressing these issues, ClinPhone® RTSM can be more rapidly implemented using pre-built, interactive web modules for patient, supply and site activities common to every study. PAREXEL Informatics can also streamline system review and approval for clients via an efficient visual design approach.
“Based upon our experience across thousands of studies, we have identified ways to standardize common functionality for patient screening, medication re-supply and other fundamental study activities,” said Xavier Flinois, President of PAREXEL Informatics. “Our customers can simplify trial management activities, and ultimately start their trials more quickly, using our powerful and flexible RTSM technology.”
“There is a growing need for faster, more efficient clinical trials, yet conducting them has become increasingly complex,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. “Trial success often hinges on start-up speed and effectiveness. At PAREXEL, we view drug development as a journey, and have made considerable investments in developing cutting-edge technology to help simplify it from beginning to end.”
ClinPhone® RTSM is available through the Perceptive MyTrials® platform and as a standalone solution. ClinPhone® RTSM and the Perceptive MyTrials® platform are also available through the Perceptive® Partner Program. For more information and a demonstration, visit PAREXEL booth #1823 at the 50th Annual Drug Information Association (DIA) Meeting, June 15-19, 2014 in San Diego.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
